Tuberculosis, Multidrug-Resistant
"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
MeSH Number(s)
C01.252.410.040.552.846.775
Concept/Terms
Tuberculosis, Multidrug-Resistant- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in Harvard Catalyst Profiles by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 3 | 2 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 6 | 0 | 6 |
| 2001 | 5 | 1 | 6 |
| 2002 | 3 | 1 | 4 |
| 2003 | 7 | 0 | 7 |
| 2004 | 11 | 3 | 14 |
| 2005 | 11 | 2 | 13 |
| 2006 | 12 | 2 | 14 |
| 2007 | 10 | 2 | 12 |
| 2008 | 10 | 1 | 11 |
| 2009 | 10 | 1 | 11 |
| 2010 | 12 | 2 | 14 |
| 2011 | 17 | 3 | 20 |
| 2012 | 35 | 0 | 35 |
| 2013 | 29 | 2 | 31 |
| 2014 | 18 | 6 | 24 |
| 2015 | 25 | 0 | 25 |
| 2016 | 33 | 4 | 37 |
| 2017 | 26 | 3 | 29 |
| 2018 | 31 | 1 | 32 |
| 2019 | 21 | 4 | 25 |
| 2020 | 28 | 2 | 30 |
| 2021 | 26 | 0 | 26 |
| 2022 | 3 | 0 | 3 |
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles.
-
Early mortality during rifampicin-resistant TB treatment. Int J Tuberc Lung Dis. 2022 Feb 01; 26(2):150-157.
-
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J. 2022 01; 59(1).
-
Tuberculosis Pathways to Care and Transmission of Multidrug Resistance in India. Am J Respir Crit Care Med. 2022 01 15; 205(2):233-241.
-
Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. Clin Infect Dis. 2021 11 02; 73(9):e3563-e3571.
-
"This is not my body": Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis. PLoS One. 2021; 16(10):e0251482.
-
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651.
-
The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2021 09 15; 204(6):629-631.
-
The incalculable costs of tuberculosis. Lancet Glob Health. 2021 10; 9(10):e1337-e1338.
-
Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19. Int J Tuberc Lung Dis. 2021 09 01; 25(9):772-775.
-
Early detection of Pre-XDR TB with line probe assay in a high TB burden country. Afr Health Sci. 2021 Sep; 21(3):968-974.